View Older Stories View More Recent Stories
-
Humacyte terminates stock sale agreement with Jefferies
-
Humacyte (HUMA) PT Lowered to $11 at Benchmark
-
Humacyte, Inc. (HUMA) Tops Q3 EPS by 5c
-
Humacyte reports long-term results for combat injury treatment in Ukraine
-
Humacyte receives U.S. patent for bioengineered esophagus technology
-
Humacyte publishes CTEV coronary bypass data, plans human trials
-
Humacyte publishes study results on Symvess for vascular complications
-
Humacyte (HUMA) files $350M mixed shelf
-
Barclays Starts Humacyte (HUMA) at Overweight
-
Humacyte (HUMA) PT Lowered to $3.50 at TD Cowen
-
Benchmark Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte (HUMA) PT Lowered to $3 at H.C. Wainwright
-
Humacyte (HUMA) PT Lowered to $7 at BTIG
-
Humacyte, Inc. (HUMA) Misses Q2 EPS by 8c
-
Humacyte (HUMA) gains Defense Logistics Agency approval for Symvess access
-
Humacyte (HUMA) PT Lowered to $14 at Benchmark
-
Humacyte, Inc. (HUMA) Tops Q1 EPS by 48c
-
TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'
-
Benchmark Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte, Inc. (HUMA) Tops Q4 EPS by 9c
-
Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess
-
Humacyte (HUMA) PT Lowered to $5 at TD Cowen
-
Humacyte (HUMA) Announces Pricing of Public Offering of Common Stock
-
Humacyte (HUMA) Announces Proposed Public Offering of Common Stock
-
Humacyte (HUMA) PT Lowered to $7.50 at TD Cowen
-
Humacyte (HUMA) Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
-
Benchmark Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte (HUMA) Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
-
Humacyte (HUMA) Announces Commercial Launch of Symvess for Extremity Vascular Trauma
-
Humacyte (HUMA) and Pluristyx Announce Gene Editing Partnership
-
Humacyte (HUMA) Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
-
HUMA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HU
-
HUMA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 17 Deadline in Securities Class Action - H
-
HUMA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
-
HUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
-
HUMA DEADLINE: ROSEN, A HIGHLY REGARDED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
HUMA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
HUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
HUMA DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
-
ROSEN, A RANKED AND LEADING FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
